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Abstract
Recent studies have identified biomarkers related to the severity and pathogenesis of co-
caine addiction and common comorbid psychiatric disorders. Monitoring these plasma me-
diators may improve the stratification of cocaine users seeking treatment. Because the
neurotrophic factors are involved in neural plasticity, neurogenesis and neuronal survival,
we have determined plasma concentrations of brain-derived neurotrophic factor (BDNF), in-
sulin-like growth factor 1 (IGF-1) and IGF-1 binding protein 3 (IGFBP-3) in a cross-sectional
study with abstinent cocaine users who sought outpatient treatment for cocaine (n = 100)
and age/body mass matched controls (n = 85). Participants were assessed with the diag-
nostic interview ‘Psychiatric Research Interview for Substance and Mental Disorders’. Plas-
ma concentrations of these peptides were not different in cocaine users and controls. They
were not associated with length of abstinence, duration of cocaine use or cocaine symptom
severity. The pathological use of cocaine did not influence the association of IGF-1 with age
observed in healthy subjects, but the correlation between IGF-1 and IGFBP-3 was not sig-
nificantly detected. Correlation analyses were performed between these peptides and other
molecules sensitive to addiction: BDNF concentrations were not associated with
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inflammatory mediators, lipid derivatives or IGF-1 in cocaine users, but correlated with che-
mokines (fractalkine/CX3CL1 and SDF-1/CXCL12) and N-acyl-ethanolamines (N-palmi-
toyl-, N-oleoyl-, N-arachidonoyl-, N-linoleoyl- and N-dihomo-γ-linolenoyl-ethanolamine) in
controls; IGF-1 concentrations only showed association with IGFBP-3 concentrations in
controls; and IGFBP-3 was only correlated with N-stearoyl-ethanolamine concentrations in
cocaine users. Multiple substance use disorders and life-time comorbid psychopathologies
were common in abstinent cocaine users. Interestingly, plasma BDNF concentrations were
exclusively found to be decreased in users diagnosed with both primary and cocaine-
induced disorders for mood and anxiety disorders. In summary, BDNF, IGF-1 and IGFBP-3
were not affected by a history of pathological use of cocaine supported by the absence of
associations with other molecules sensitive to cocaine addiction. However, BDNF was af-
fected by comorbid mood disorders. Further research is necessary to elucidate the role of
BDNF and IGF-1 in the transition to cocaine addiction and associated
psychiatric comorbidity.
Introduction
Chronic cocaine use induces long-lasting neurochemical, structural and behavioral adaptive
changes thought to result from altered gene and protein expression within cerebral areas play-
ing a critical role in addiction and reward [1]. Some of these changes are not fully reversed
upon prolonged abstinence, and may represent an example of aberrant cocaine-induced neuro-
plastic changes related to cocaine dependence and an increased susceptibility to relapse to drug
taking even after a long period of abstinence [2,3].
Furthermore, long-term cocaine use is commonly associated with altered executive func-
tions, impaired emotional processing capacity and a higher incidence of comorbid mental dis-
orders, particularly mood and anxiety disorders [4,5,6]. The diagnosis of psychiatric
comorbidity is an important consideration for effective therapies to overcome cocaine addic-
tion. However, the accurate diagnosis of comorbid psychiatric disorders in cocaine addicts has
to face two major problems, the effects of cocaine can conceal symptoms of other mental disor-
ders and the diagnosis is defined by manifestations rather than by direct biomarkers [7,8].
Focusing on this last point, the search for peripheral biomarkers for both psychiatric and
substance use disorders has caused an increasing interest in addiction psychiatry research over
the last few years. This growing research has generated a number of putative biomarkers, main-
ly involving the immune system and inflammatory responses, which still require replication in
larger studies [9,10,11]. Recently, our group has studied the plasma profile of inflammatory
mediators and fatty acid derivatives in abstinent cocaine users under outpatient treatment
[12,13]. We found certain cytokines and chemokines that might serve as reliable biomarkers
for pathological use of cocaine (i.e., binge use and/or chronic use) and symptom severity [12].
Additionally, several fatty acid derivatives such as endocannabinoids and congeners were bio-
markers for cocaine use disorders and psychiatric comorbidity [13].
Neurotrophic factors are peptides that are known for their role in mediating neuronal plas-
ticity and neuronal growth. In addition to neurons, these factors are produced by other cells
and can affect and integrate neural, immune and endocrine systems. They have been reported
to mediate the effects of drugs for the treatment of mental disorders but also play a relevant
role in the acute and chronic responses produced by addictive drugs [14]. We have focused this
Growth Factors and Cocaine Addiction
PLOS ONE | DOI:10.1371/journal.pone.0118610 March 3, 2015 2 / 20
Andalucía (PI0228-2013 and PI0823-2012);
Departament d’Innovació, Universitats i Empresa,
Generalitat de Catalunya (2014-SGR-680). JS, AS
and FJP hold a “Miguel Servet” research contract
from ISC-III (CP12/03109, CP14/00173 and CP14/
00212, respectively). PR-S holds a “Río Hortega”
research contract from ISC-III (CM13/0115). EC-O
holds a “Sara Borrell” research contract from ISC-III
(CD12/00455). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: Rafael de la Torre is a Plos
ONE Editorial Board member, but this does not alter
the authors’ adherence to PLOS ONE Editorial
policies and criteria. The other authors declare no
conflicts of interest.
study on two trophic factors, which are found in plasma and involved in mediating neuronal
plasticity, the brain-derived neurotrophic factor (BDNF) and the insulin-like growth factor 1
(IGF-1). In addition to IGF-1, we have also measured the IGF binding protein 3 (IGFBP-3) as
relevant protein modulating its effects.
BDNF is a neurotrophin that participates in neuronal survival, differentiation, synaptogen-
esis and maintenance. Accumulating evidence suggests that alterations in the BDNF expression
underlie a variety of psychiatric and neurological disorders. BDNF has been associated posi-
tively with some disorders (e.g., major depression and bipolar disorder) but there are also
many non-specific or conflicting findings (schizophrenia and autism) [11,15]. Furthermore,
BDNF has been also evaluated in cocaine addiction and comorbid disorders. Indeed, serum
BDNF concentrations have been recently postulated as an indication of relapse risk during
early recovery from cocaine dependence in a prospective study [16]. Another study performed
by Corominas-Roso and colleagues showed that an increase in serum BDNF concentrations
during early abstinence correlates with cocaine craving and abstinence symptoms [17], but in-
terestingly these increased BDNF concentrations are not observed in patients displaying co-
caine-induced psychosis [18].
IGF-1 is a trophic mediator regulated by growth hormone (GH) that may either be free or
bound to binding proteins. IGFBP-3 is the most abundant binding protein in human blood
and this complex prolongs the half-life of IGF-1. IGF-1 regulates proliferation, development
and growth of neural cells (for recent reviews [19,20]). This peptide is also involved in the path-
ogenesis and evolution of psychiatric disorders in preclinical models [21,22] and clinical cases
in old [23] and young [24] individuals. Thus, a cross-sectional study in older adults showed
that the association between depressive symptoms and memory deficits is stronger with lower
concentrations of circulating IGF-1 [23]. Young adults with GH deficiency exhibit anxious or
depressed moods, which can be treated by GH therapy that increases IGF-1 concentrations.
Furthermore, IGF-1 concentrations negatively correlate with depression, fatigue, tension and
anxiety and positively with vigor and memory [24]. Regarding drugs of abuse in humans, IGF-
1 concentrations have been assessed in alcohol and opiate dependence. Studies in alcohol de-
pendents revealed a positive correlation between blood insulin level and alcohol craving, but
not between alcohol craving and IGF-1 concentrations during either the active drinking phase
or during abstinence [25]. In contrast to alcohol, serum IGF-1 is found to be elevated in opiate
dependence [5].
The aim of the present cross-sectional study is to examine the plasma concentrations of
BDNF, IGF-1 and IGFBP-3 in a cohort of abstinent cocaine users on an outpatient basis ac-
cording to cocaine use history (duration of use, length of abstinence and cocaine symptom se-
verity) and the comorbidity of other mental disorders. We found that plasma BDNF, IGF-1
and IGFBP-3 are unaltered in abstinent cocaine users but they are affected by the presence of
comorbid mood and anxiety disorders.
Methods and Materials
1 Subjects and recruitment
All participants in the present cross-sectional study were white Caucasians grouped into absti-
nent cocaine users and healthy controls. One-hundred and ten cocaine users were enrolled
from outpatient treatment programs for cocaine addiction in the province of Málaga (Spain)
for a 36 month- period (2011–2013). Eighty healthy individuals were recruited in parallel from
a multidisciplinary staff working at the Hospital Regional Universitario de Málaga.
Cocaine users had to meet eligibility criteria based on inclusion and exclusion criteria. Inclu-
sion criteria were as follows:18 years to 65 years of age, intranasal cocaine use, diagnosis of a
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lifetime ‘pathological use’ of cocaine (chronic intoxication and/or binge), and abstinence from
cocaine for at least 2 weeks before testing. The ‘pathological use’ of cocaine was determined
through a psychiatric interview, while the abstinence of cocaine users was checked weekly by
urine analysis in the outpatient treatment centers for cocaine addiction and plasma analyses
[12]. Exclusion criteria were as follows: personal history of chronic diseases (e.g. cardiovascu-
lar, respiratory, renal, hepatic, neurological or endocrine diseases), personal history of cancer,
infectious diseases, incapacitating cognitive alterations and/or severe schizophrenia,
and pregnancy.
Controls were matched with the cocaine group for age and body mass index (BMI) and they
were required to be18 years to 65 years of age. In addition to the mentioned exclusion crite-
ria for abstinent cocaine users, controls were excluded with: personal history of drug abuse and
lifetime psychiatric disorders.
2 Clinical assessments
All cocaine users were evaluated according to ‘Diagnostic and Statistical Manual of Mental Dis-
orders-4th Edition-Text Revision’ (DSM-IV-TR) criteria, using the Spanish version of the ‘Psy-
chiatric Research Interview for Substance and Mental Disorders’ (PRISM) [7,26]. Controls
were initially evaluated by PRISM (for substance screening and abuse and dependence) and
subsequently by the Spanish version of the ‘Composite International Diagnostic Interview’
(CIDI) for the detection of psychiatric disorders [27]. All the interviews were performed by ex-
perienced psychologists who had received both PRISM and CIDI training.
2.1 Psychiatric Research Interview for Substance and Mental Diseases (PRISM). The
PRISM is a semi-structured interview that has demonstrated good psychometric properties in
terms of test-retest reliability [28], inter-rater reliability [29] and validity [7] to diagnose psy-
chiatric disorders among substance users.
Diagnoses were made using two time-frames: ‘current’ (criteria were met within the past
year) and ‘past’ (criteria were met before the previous 12 months). Lifetime prevalence, taking
into account both current and past diagnoses, was used to present the frequency of substance
use disorders, non-substance use disorders and psychiatric comorbidity. In addition to the di-
agnoses of substance abuse and dependence, the PRISM differentiates ‘pathological use’
(chronic intoxication: substance use4 days a week for3 weeks; and/or binge use:3 conse-
cutive days of continuous substance use) from ‘occasional use’ (substance use less than 4 days a
week, unless substance was used in a binge pattern).
The cocaine symptom severity was assessed combining the DSM-IV-TR criteria for cocaine
use disorders: 7 dependence criteria (for diagnosis of dependence three or more co-occurring
symptoms in a 12-month period are required); and 4 abuse criteria (one symptom is necessary
for diagnosis of abuse), which is in agreement with the unidimensionality of DSM-5 criteria
[30,31]. More details regarding analysis of cocaine symptom severity have been described pre-
viously (see [13]).
3 Laboratory methods for human samples
3.1 Collection and analysis of plasma samples. Blood samples were obtained in the
morning (09:00–11:00 h AM) after fasting for 8–12 h (previous to the psychiatric interviews).
Venous blood was collected into 10 mL K2-EDTA tubes (BD, Franklin Lakes, NJ, USA) and
processed to obtain plasma. Blood samples were centrifuged at 2,200×g for 15 min (4°C) and
individually assayed for detecting infectious diseases by 3 rapid tests for HIV (Retroscreen
HIV, QualPro Diagnostics-Tulip Group Ltd, Goa, India), hepatitis B (HBsAg Test, Toyo
Diagnostics-Turklab Inc., Izmir, Turkey) and hepatitis C (Flaviscreen HCV, QualPro
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Diagnostics-Tulip Group Ltd, Goa, India). Samples testing positive were discarded following
safety protocols.
Plasma analyses for cocaine metabolite (Benzoylecgonine Specific Direct ELISA Kit Immu-
nalysis, Pomona, CA, USA) were performed to confirm cocaine abstinence. Four cocaine users
who tested negative for drugs of abuse in urine analyses at the outpatient treatment centers for
cocaine addiction were positive for benzoylecgonine in plasma, and these cocaine users were
excluded from this study. Plasma samples were stored at -80°C until further analyses.
3.2 Multiplex immunoassay analysis. A Bio-Plex Suspension Array System 200 (Bio-Rad
Laboratories, Hercules, CA, USA) was used to quantify the plasma concentrations of anti- and
pro-inflammatory cytokines, homeostatic and pro-inflammatory chemokines and BDNF fol-
lowing the manufacturer´s instructions as previously reported [12]. Human protein panels
were used to simultaneously detect the following analytes: Tumor necrosis factor-alpha
(TNFα); interleukin-1 beta (IL-1β); interleukin-6 (IL-6); interleukin-10 (IL-10); CX3CL1 [Che-
mokine (C-X3-C motif) ligand 1], commonly referred to as fractalkine; CCL2 [Chemokine
(C-C motif) ligand 2], also referred to as monocyte chemotactic protein-1 (MCP-1); CXCL12
[Chemokine (C-X-C motif) ligand 12], also referred to stromal cell-derived factor-1 (SDF-1);
and BDNF. Raw data (mean fluorescence intensity) were analyzed using the Bio-Plex Manager
Software 4.1 (Bio-Rad Laboratories, Hercules, CA, USA). Data of plasma concentrations (pg of
protein/mL) were used to perform multiple correlation studies and analyses of the means.
3.3 Radioimmunoassay analysis for IGF1 and IGFBP-3. Plasma concentrations of total
IGF-1 were estimated by double antibody radioimmunoassay (RIA), after removal of serum
IGFBPs by acid-ethanol extraction. To confirm the removal of IGFBPs, extracted and non-
extracted plasma fractions were incubated with 125I-IGF-1 at 4°C for 24 h. Dextran charcoal
was used to separate the bound and free tracers. The IGF-1 antiserum (UB2–495) was a gift
from Drs Underwood and VanWisk distributed by the Hormone Distribution Program of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the Na-
tional Hormone and Pituitary Program. Concentrations of IGF-1 were expressed in terms
of rat IGF-1 from Gropep Bioreagents Pty Ltd (Adelaide, SA, Australia). Test sensitivity was
10 ng/mL and the intra-assay coefficient of variation was 8%. All samples were run in the
same batch.
Plasma IGFBP-3 concentration was determined in duplicate by RIA using a commercially
available kit (Mediagnost GmbH, Reutlingen, Germany) following the manufacturer´s proto-
col. The assay sensitivity was 500 pg/mL and the intra-assay coefficient of variation was 7.5%.
3.4 Quantification of acyl derivatives. The following lipid derivatives and their respective
deuterated forms were used for quantification: N-stearoyl-ethanolamine (SEA), N-palmitoyl-
ethanolamine (PEA) and PEA-d4, N-oleoyl-ethanolamine (OEA) and OEA-d4, N-palmito-
leoyl-ethanolamine (POEA), N-arachidonoyl-ethanolamine (AEA) and AEA-d4, N-linoleoyl-
ethanolamine (LEA) and LEA-d4, N-docosahexaenoyl-ethanolamine (DHEA) and DHEA-d4,
N-dihomo-γ-linolenoyl-ethanolamine (DGLEA), 2-arachidonoyl-glycerol (2-AG) and 2-AG-
d5, and 2-linoleoyl-glycerol (2-LG). PEA-d4, OEA-d4 and AEA-d4 were used for quantification
of POEA, SEA and DGLEA respectively, since their deuterated forms were not commercially
available. All reagents were obtained from Cayman Chemical (Ann Arbor, MI, USA).
Sample extraction and the chromatographic separation were performed in a Liquid Chro-
matography-tandemMass Spectrometry System (Agilent Technologies, Wilmington, DE,
USA) as previously reported [13]. The tandem quadrupole mass spectrometer operated on the
positive electrospray mode. The multiple reaction monitoring mode was used for the analysis
with the following precursor to product ion transitions: m/z 328.1/62 for SEA, m/z 300.1/62 for
PEA, m/z 304.4/66 for PEA-d4, m/z 326.1/62 for OEA, m/z 330.4/66 for OEA-d4, m/z 298.2/62
for POEA, m/z 348.3/62 for AEA, m/z 352.2/66 for AEA-d4, m/z 324.5/62 for LEA, m/z 328.5/
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66 for LEA-d4, m/z 372.6/62 for DHEA, m/z 376.3/66 for DHEA-d4, m/z 350.2/62 for DGLEA,
m/z 379.2/287 for 2-AG, m/z 384.3/287 for 2-AG-d5 and m/z 355.2/263 for 2-LG. A six-point
external calibration curve prepared in the mobile phase (10:90, A:B) and spiked with 0.4–25 ng
of N-acyl-ethanolamines and 0.8–50 ng of 2-acyl-glycerols was used for the quantification
[32]. Data of plasma concentration (ng of acyl derivative /mL) were used to perform multiple
correlation studies.
4 Ethics statement
Written informed consent was obtained from each subject after they had received a complete
description of the present study and had been given the chance to discuss any questions or is-
sues. The study and protocols for recruitment were approved by the Ethics Committee of the
Hospital Regional Universitario de Málaga (07/19/2009 PND049/2009 and PI0228–2013; CEI
Provincial de Málaga) and therefore were conducted in accordance with the Declaration of
Helsinki (seventh revision in 2013, Fortaleza, Brazil).
5 Statistical analyses
All data for graphs and tables are expressed as number and percentage of subjects [n (%)] or
mean and standard deviation (SD) of concentrations [mean (SD)]. The significance of differ-
ences in categorical variables was determined by using the Fisher’s exact test; while continuous
variables were evaluated by different statistical approaches according to the number of compar-
isons and the distribution of variables. For comparisons of two groups, the Student’s t-test was
used for normally distributed continuous variables and the Mann-Whitney U test was used as
non-parametric test. For comparisons of three or more groups, one-way and analysis of vari-
ance (ANOVA) with Bonferroni correction for multiple comparisons was used for normal dis-
tributions whereas the Kruskal—Wallis analysis with the Dunn’s post test was used as non-
parametric analysis. Correlation analyses were performed by using the Pearson´s correlation
coefficient (r) for continuous variables with normal distribution and Spearman´s rank correla-
tion coefficient (rho) for continuous variables without normality and discrete variables. The
Holm-Bonferroni correction was employed for multiple comparisons of correlation coeffi-
cients for controlling the type I errors. The normal distribution of variables was evaluated
using the D’Agostino & Pearson omnibus normality test. Thresholds of 0.05 were applied for
p-values and adjusted p-values. Statistical analyses were performed using the computer pro-
gram Graph-Pad Prism version 5.04 (GraphPad Software, San Diego, CA, USA).
Results
1 Sample demographics and clinical characteristics
A total of 185 subjects both sexes were selected for this study and grouped into the cocaine
(n = 100) and control (n = 85) groups. The average participant was a 36–37 year-old male with
a BMI of 26 (weighing 75–77 kg). A description of the sample is presented in Table 1.
Cocaine users displayed cocaine abstinence for 234.7 (436.3) days [mode: 30 days (range:
2,555)]. The percentages of cocaine users treated for substance use and psychological condition
were 81.0% and 35.0% respectively. In contrast, only 17.6% of controls received
psychological treatments.
Cocaine use disorders were the most prevalent lifetime substance use disorders (89%) fol-
lowed by lifetime alcohol (64%), cannabis (23%), benzodiazepines (8%) and heroin (8%) use
disorders (not including caffeine or nicotine).
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Regarding common psychiatric disorders assessed with the PRISM, we found high preva-
lences of comorbid mood (33%), anxiety (22%), psychosis (13%) and personality (31%) disor-
ders. Therefore, a vast majority of cocaine users who participated in this study were diagnosed
with substance use disorders or multiple substance use disorders and psychiatric comorbidity.
2 Plasma concentrations of BDNF, IGF-1 and IGFBP-3
Mean plasma concentrations for BDNF, IGF-1 and IGFBP-3 were similar in both groups. The
plasma concentrations of each protein were as follows: 274.9±200.3 pg/mL and 269.4±242.7
pg/mL for BDNF, 212.2±63.9 ng/mL and 210.7±51.2 ng/mL for IGF-1, and 3.91±0.94 μg/mL
and 3.78±0.93 μg/mL for IGFBP-3, in the cocaine and control groups respectively.
2.1 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to sex. As indicat-
ed in Fig. 1, we examined whether the sex composition in the cocaine and control groups af-
fects the plasma concentrations of BDNF, IGF-1 and IGFBP-3. A two-way ANOVA was
performed taking into consideration cocaine use and sex as factors. We did not observe main
effects or interaction of these factors on the concentrations of BDNF, IGF-1 and IGFBP-3 be-
tween men and women in both groups.
2.2 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to age. The influ-
ence of age on growth factors has been extensively described, especially with IGF-1 [33,34,35].
Table 1. Baseline socio-demographic variables and lifetime psychiatric and substance use disorders.
VARIABLE COCAINE GROUP CONTROL GROUP p-value
n = 100 n = 85
AGE (18) [MEAN (SD)] 35.8 (8.9) 37.3 (10.7) 0.299 a
SEX [n (%)] Women 18 (18.0) 25 (29.4) 0.081 b
Men 82 (82.0) 60 (70.6)
BODY MASS [MEAN (SD)] Body Mass Index 25.5 (4.5) 26.1 (4.0) 0.343 a
Weight (kg) 77.1 (14.4) 75.3 (11.0) 0.337 a
PSYCHOLOGICAL TREATMENT (EVER) [n (%)] No 67 (67.0) 80 (94.1) <0.001 b
Yes 35 (35.0) 5 (5.9)
SUBSTANCE USE TREATMENT (EVER) [n (%)] No 21 (21.0) 85 (100) <0.001 b
Yes 81 (81.0) 0 (0.0)
LIFETIME SUBSTANCE USE DISORDERS [n (%)] Cocaine 89 (89.0) - -
Alcohol 64 (64.0) -
Cannabis 23 (23.0) -
Benzodiazepines 8 (8.0) -
Heroin 8 (8.0) -
Hallucinogens 6 (6.0) -
Others 7 (7.0) -
LIFETIME COCAINE USE DISORDERS [n (%)] Abuse or Dependence 89 (89.0) - -
Abuse 78 (78.0) -
Dependence 84 (84.0) -
LIFETIME COMMON PSYCHIATRIC DISORDERS [n (%)] Mood Disorders 33 (33.0) - -
Anxiety Disorders 22 (22.0) -
Psychosis Disorders 13 (13.0) -
Personality Disorders 31 (31.0) -
a p-value from Student’s t-test.
b p-value from Fisher’s exact test or Chi-square test.
doi:10.1371/journal.pone.0118610.t001
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Fig 1. Plasma concentrations of BDNF, IGF-1 and IGFBP-3 according to sex in abstinent cocaine
users and control subjects. A) BDNF (pg/mL);B) IGF-1 (ng/mL); andC) IGFBP-3 (μg/mL). Bars are the
means and SD. Data were analyzed by two-way analyses (cocaine use [cocaine group and control group]
and sex [women and men]).
doi:10.1371/journal.pone.0118610.g001
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Correlation analyses were performed between plasma concentrations of BDNF, IGF-1 or
IGFBP-3 and age for each study group, as shown in Fig. 2. The plasma IGF-1 concentrations
were negatively correlated with age in the cocaine (r = -0.33, p<0.001) and control (r = -0.32,
p<0.001) groups using the Pearson’s correlation coefficient for normal distributions. These
correlations were not significant for BDNF and IGFBP-3 concentrations.
Fig 2. Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3 and age in abstinent cocaine users (black circles) and
control subjects (white circles). A) BDNF (pg/mL); B) IGF-1 (ng/mL); andC) IGFBP-3 (μg/mL). Dots are individual values. (r) Pearson´s correlation
coefficient; (rho) Spearman´s correlation coefficient; (p) p-value for statistical significance.
doi:10.1371/journal.pone.0118610.g002
Growth Factors and Cocaine Addiction
PLOS ONE | DOI:10.1371/journal.pone.0118610 March 3, 2015 9 / 20
3 Multiple correlation analyses of BDNF, IGF-1 and IGFBP-3 with other
plasma molecules sensitive to cocaine addiction
We determined the degree of association among these peptides (BDNF, IGF-1 and IGFBP-3)
and other plasma mediators in the cocaine and control groups. Recently, we have reported that
certain circulating pro-inflammatory mediators and fatty acid derivatives are influenced by co-
caine addiction [12,13]. Thus, we examined the degree of association of BDNF, IGF-1 and
IGFBP-3 with these molecules and among themselves in the sample. The significances of the
resulting correlation coefficients were statistically corrected using the Holm-Bonferroni meth-
od to counteract the problem of multiple comparisons for the control and cocaine groups.
3.1 BDNF. Plasma concentrations of BDNF showed a non-normal distribution in absti-
nent cocaine subjects and controls and the correlation coefficients calculated were rho
(Table 2).
In the cocaine group, BDNF concentrations did not correlate with the concentrations of
chemokines (CX3CL1, CCL2 and CXCL12), cytokines (IL1β, TNFα, IL6 and IL10), fatty acid
derivatives (N-acyl-ethanolamines and 2-acyl-glycerols), IGF-1 or IGFBP-3. In contrast,
BDNF concentrations correlated positively with the concentrations of certain chemokines and
N-acyl-ethanolamines in the control group. Concretely, BDNF significantly correlated with
CX3CL1 (rho = +0.69, adjusted p<0.001) and CXCL12 (rho = +0.78, adjusted p<0.001); PEA
Table 2. Multiple correlations between plasma concentrations of BDNF and other plasma molecules in the cocaine group.
MULTIPLE CORRELATION ANALYSIS 1,2
VARIABLE BDNF
COCAINE CONTROL
rho p-value adjusted p-value rho p-value adjusted p-value
CX3CL1 (fractalkine) -0.094 0.441 ns +0.693 <0.001 <0.001
CCL2 (MCP-1) -0.005 0.968 ns +0.009 0.941 ns
CXCL12 (SDF-1) -0.110 0.363 ns +0.784 <0.001 <0.001
IL1β -0.109 0.372 ns -0.135 0.269 ns
TNFα -0.133 0.272 ns -0.189 0.120 ns
IL6 -0.260 0.029 ns +0.054 0.660 ns
IL10 -0.110 0.365 ns +0.031 0.799 ns
SEA -0.047 0.695 ns +0.325 0.007 ns
PEA -0.058 0.629 ns +0.492 <0.001 0.003
OEA -0.133 0.270 ns +0.400 <0.001 0.033
POEA -0.037 0.760 ns +0.331 0.006 ns
AEA -0.150 0.213 ns +0.447 <0.001 0.005
LEA -0.187 0.119 ns +0.423 <0.001 0.014
DGLEA -0.170 0.156 ns +0.524 <0.001 0.002
DHEA +0.009 0.938 ns +0.301 0.012 ns
2-AG +0.074 0.538 ns +0.054 0.661 ns
2-LG -0.056 0.640 ns +0.122 0.320 ns
IGF-1 -0.157 0.210 ns -0.111 0.291 ns
IGFBP-3 -0.170 0.156 ns -0.221 0.106 ns
1 All variables were assessed for normality to select the adequate correlation coefﬁcient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).
Abbreviations: ns, non-signiﬁcant.
doi:10.1371/journal.pone.0118610.t002
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(rho = +0.49, adjusted p<0.01), OEA (rho = +0.40, adjusted p<0.05), AEA (rho = +0.45, ad-
justed p<0.01), LEA (rho = +0.42, adjusted p<0.05) and DGLEA (rho = +0.52, adjusted
p<0.01). Although BDNF was initially associated with other N-acyl-ethanolamines (SEA,
POEA and DHEA), the statistical adjustment for multiple comparisons rejected them.
3.2 IGF-1. Plasma concentrations of IGF-1 were normally distributed in the cocaine and
control groups and Pearson´s correlation coefficients (r) were calculated for all comparisons.
As shown in Table 3, IGF-1 concentrations did not correlate with the concentrations of the
plasma molecules that were assessed in the cocaine group. Only we found an initial association
with its binding protein IGFBP-3 prior to apply the correction test that was rejected. However,
in the control group this positive correlation between the concentrations of IGF-1 and IGFBP-
3 was significant after adjusting the significance (r = +0.46, adjusted p<0.01). Similar to
BDNF, IGF-1 showed correlations with some N-acyl-ethanolamines (PEA and OEA) that were
also discarded after correcting them.
3.3 IGFBP-3. As indicated in Table 4, IGFBP-3 concentrations passed the normality test
in both groups and Pearson´s correlation coefficients (r) were calculated. In the cocaine group,
plasma concentrations of IGFBP-3 were not associated with the plasma mediators that were ex-
amined with the exception of SEA. Thus, plasma concentrations of IGFBP-3 correlated posi-
tively with SEA (r = +0.40; adjusted p<0.05). Regarding control subjects, IGFBP-3
concentrations were not correlated with the rest of molecules although some positive
Table 3. Multiple correlations between plasma concentrations of IGF-1 and other plasma molecules in the cocaine group.
MULTIPLE CORRELATION ANALYSIS 1,2
VARIABLE IGF-1
COCAINE CONTROL
r p-value adjusted p-value r p-value adjusted p-value
CX3CL1 (fractalkine) -0.062 0.608 ns -0.062 0.792 ns
CCL2 (MCP-1) +0.087 0.472 ns +0.087 0.137 ns
CXCL12 (SDF-1) +0.013 0.914 ns +0.013 0.845 ns
IL1β +0.067 0.582 ns +0.067 0.180 ns
TNFα +0.048 0.693 ns +0.048 0.638 ns
IL6 +0.078 0.519 ns +0.078 0.520 ns
IL10 +0.089 0.462 ns +0.089 0.799 ns
SEA +0.086 0.436 ns +0.086 0.187 ns
PEA +0.054 0.624 ns -0.281 0.019 ns
OEA -0.064 0.560 ns -0.264 0.028 ns
POEA -0.142 0.195 ns +0.006 0.964 ns
AEA -0.085 0.437 ns -0.186 0.125 ns
LEA -0.095 0.387 ns -0.133 0.275 ns
DGLEA -0.018 0.873 ns -0.184 0.131 ns
DHEA +0.171 0.118 ns -0.309 0.010 ns
2-AG -0.120 0.275 ns -0.097 0.430 ns
2-LG -0.074 0.503 ns -0.119 0.331 ns
IGFBP-3 +0.327 0.006 ns +0.463 <0.001 0.003
1 All variables were assessed for normality to select the adequate correlation coefﬁcient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).
Abbreviations: ns, non-signiﬁcant.
doi:10.1371/journal.pone.0118610.t003
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associations were observed in paired-comparisons with cytokines (IL1β, IL6 and IL10) without
adjustment for multiple comparisons.
Overall, while BDNF concentrations correlated positively with chemokines and N-acyl-
ethanolamines in the control group, IGFBP-3 was found to be positively associated only with
SEA in the cocaine group. Moreover, IGF-1 and IGFBP-3 correlated positively in the control
group but not in the cocaine group.
4 Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in relation to
variables associated with cocaine use
In the cocaine group, correlation analyses were performed between plasma concentrations of
BDNF, IGF-1 or IGFBP-3 and length of cocaine abstinence (days) and duration of cocaine use
(years) (S1 Fig.). Because both length of cocaine abstinence and duration of cocaine were vari-
ables with a non-normal distribution, Spearman’s rank correlation coefficients (rho) were used
for determining associations. However, we observed no correlations between these mediators
and variables related to abstinence and cocaine use.
Additional correlation analyses were performed between plasma concentrations of BDNF,
IGF-1 or IGFBP-3 and individual scores of DSM-IV-TR criteria for cocaine abuse and depen-
dence. The concentrations of these peptides were not associated with the cocaine symptom se-
verity (S2 Fig.). As expected, the cocaine group displayed an increased number of criteria for
cocaine use disorders (7.3±3.3 criteria) which indicates a high cocaine symptom severity.
Table 4. Multiple correlations between plasma concentrations of IGFBP-3 and other plasma molecules in the cocaine group.
MULTIPLE CORRELATION ANALYSIS 1,2
VARIABLE IGFBP-3
COCAINE CONTROL
r p-value adjusted p-value r p-value adjusted p-value
CX3CL1 (fractalkine) -0.006 0.963 ns +0.113 0.356 ns
CCL2 (MCP-1) +0.126 0.303 ns +0.171 0.159 ns
CXCL12 (SDF-1) -0.113 0.357 ns +0.141 0.250 ns
IL1β -0.062 0.611 ns +0.317 0.008 ns
TNFα -0.047 0.699 ns +0.233 0.054 ns
IL6 +0.067 0.587 ns +0.321 0.007 ns
IL10 -0.052 0.672 ns +0.244 0.044 ns
SEA +0.397 <0.001 0.011 -0.091 0.459 ns
PEA +0.216 0.058 ns -0.048 0.696 ns
OEA -0.226 0.056 ns +0.115 0.348 ns
POEA -0.121 0.272 ns +0.046 0.710 ns
AEA -0.079 0.473 ns +0.125 0.307 ns
LEA +0.038 0.732 ns -0.003 0.979 ns
DGLEA -0.084 0.446 ns +0.006 0.963 ns
DHEA +0.042 0.707 ns +0.079 0.521 ns
2-AG +0.010 0.926 ns +0.145 0.235 ns
2-LG +0.093 0.398 ns +0.132 0.280 ns
1 All variables were assessed for normality to select the adequate correlation coefﬁcient (r; rho).
2 Adjusted p-values were calculated using Holm-Bonferroni correction (3x18 correlations per group).
Abbreviations: ns, non-signiﬁcant.
doi:10.1371/journal.pone.0118610.t004
Growth Factors and Cocaine Addiction
PLOS ONE | DOI:10.1371/journal.pone.0118610 March 3, 2015 12 / 20
5 Psychiatric comorbidity and substance use disorders
Because all outpatient cocaine users display high rates of comorbid psychiatric disorders, we
evaluated plasma concentrations of BDNF, IGF-1 and IGFBP-3 in the most common psychiat-
ric comorbidities among substance users, as shown in Table 5.
The DSM-IV-TR Axis I disorders included mood disorders, anxiety and psychosis. Consid-
ering the exclusive diagnoses, the prevalences of cocaine-induced mood and psychotic (18.0%
and 11.0% respectively) disorders were higher than the primary mood and psychotic (11.0%
and 2.0% respectively) disorders, unlike cocaine-induced and primary anxiety disorders (7.0%
and 12.0% respectively). Also, some cocaine users were diagnosed with both primary and co-
caine-induced mood (n = 5) and anxiety (n = 3) disorders. With respect to personality disor-
ders, the prevalence reached a 31.0%.
Considering the plasma concentrations of BDNF, IGF.1 and IFGBP-3 in these outpatient
users diagnosed with psychiatric comorbidities, we only observed significant changes in BDNF
concentrations. Concretely, abstinent cocaine users diagnosed with both primary and cocaine-
induced disorders (for mood or anxiety disorders) displayed significant decreases in plasma
BDNF concentrations (p<0.05) compared to those users with no mood disorders or no anxi-
ety. Additionally, the decrease in BDNF concentrations in subjects diagnosed with both prima-
ry and cocaine-induced anxiety disorders were also significant (p<0.05) relative to the
control group.
Table 5. Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in abstinent cocaine users grouped by diagnosis of common psychiatric disorders
in substance users.
VARIABLE
PSYCHIATRIC DISORDER n (%) BDNF pg/mL [mean (SD)] IGF-1 ng/mL [mean (SD)] IGFBP-3 μg/mL [mean (SD)]
MOOD DISORDERS1 33 (33.0) 240.2 (177.4) 213.1 (83.4) 3.83 (0.99)
Primary 11 (11.0) 297.0 (223.2) 246.4 (59.7) 4.31 (0.73)
Cocaine-induced 17 (18.0) 227.6 (150.4) 196.5 (91.8) 3.83 (1.07)
Primary & Cocaine-induced 5 (5.0) 131.8 (66.7) a 186.5 (38.8) 3.30 (0.67)
NO MOOD DISORDERS 67 (67.0) 294.9 (211.4) 210.8 (52.5) 3.87 (0.92)
ANXIETY DISORDERS 22 (22.0) 268.2 (171.1) 191.6 (61.9) 3.80 (0.91)
Primary 12 (12.0) 278.9 (170.0) 182.3 (67.6) 3.84 (0.87)
Cocaine-induced 7 (7.0) 293.6 (199.3) 199.9 (67.2) 4.11 (1.09)
Primary & Cocaine-induced 3 (3.0) 137.9 (0.9) b,* 209.8 (16.0) 3.16 (0.75)
NO ANXIETY DISORDERS 78 (78.0) 276.8 (208.9) 217.1 (63.7) 3.94 (0.95)
PSYCHOTIC DISORDERS 13 (13.0) 262.9 (209.9) 206.7 (59.3) 3.83 (0.84)
Primary 2 (2.0) 163.4 (168.1) 178.5 (0.0) 3.49 (0.30)
Cocaine-induced 11 (11.0) 281.0 (218.4) 211.0 (62.9) 3.89 (0.90)
Primary & Cocaine-induced - - - -
NO PSYCHOTIC DISORDERS 87 (87.0) 277.2 (199.9) 213.0 (64.8) 3.92 (0.95)
PERSONALITY DISORDERS (CLUSTER-B) 2 31 (31.0) 232.8 (176.8) 197.0 (64.5) 3.83 (0.91)
NO PERSONALITY DISORDERS 69 (69.0) 294.5 (208.9) 218.1 (63.4) 3.94 (0.95)
CONTROL GROUP 269.4 (242.7) 210.7 (51.2) 3.78 (0.93)
1 Mood disorders include major depressive disorder, dysthymic disorder, bipolar disorders (mania and hypomania) and cocaine-induced mood disorders.
2 Cluster B personality disorders include borderline and antisocial personality disorders.
a p<0.05 denotes signiﬁcant differences compared to the no mood disorders subgroup.
b p<0.05 denotes signiﬁcant differences compared to the no anxiety disorders subgroup.
* p<0.05 denotes signiﬁcant differences compared to the control group.
doi:10.1371/journal.pone.0118610.t005
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Regarding IGF-1 and IGFBP-3, we observed no changes in their plasma concentrations by
the presence of psychiatric comorbidities.
Discussion
The present exploratory and cross-sectional study found that the plasma concentrations of
BDNF and IGF-1 are unaltered by a lifetime pathological use of cocaine in abstinent cocaine
users under treatment. Indeed, plasma concentrations of these factors were not influenced by
the length of abstinence, duration of cocaine use or cocaine symptom severity. The association
of plasma IGF-1 concentrations with age was not affected by the pathological use of cocaine, al-
though the association of IGF-1 and IGFBP-3 did not reach statistical significance after correct-
ing it in abstinent cocaine users. Additionally, the correlations of BDNF concentrations with
chemokines and N-acyl-ethanolamines in the control group were not observed in cocaine sub-
jects. However, we detected a positive correlation between the concentrations of IGFBP-3 and
SEA in the cocaine group. On the other hand, we found an elevated prevalence of comorbid
psychiatric disorders in these patients with polysubstance use and changes in BDNF concentra-
tions related to the diagnosis of mood and anxiety disorders. Thus, plasma BDNF concentra-
tions were reduced in cocaine users diagnosed with both primary and cocaine-induced mood
and anxiety disorders.
BDNF in abstinent cocaine users
Although we found no changes in BDNF concentrations, several clinical studies have reported
changes in the serum BDNF concentrations of cocaine dependents during abstinence, suggest-
ing that BDNF is a reliable biomarker for cocaine addiction. A first study in cocaine dependent
individuals found that BDNF concentrations are increased during early abstinence, and the ele-
vated BDNF is predictive of relapse risk during early recovery from cocaine dependence [16].
Related to this finding, another study reported that BDNF concentrations are positively corre-
lated with cocaine craving and abstinence symptoms [17]. Similarly, more recent studies in
crack cocaine dependent individuals have found high blood BDNF concentrations during early
abstinence [36] and negative correlations with severity [37] and amount of cocaine used [38].
All these prospective studies were conducted in cocaine addicts following inpatient detoxifica-
tion treatments during 2–4 weeks, unlike our study that is a cross-sectional study in cocaine
users seeking treatment in outpatient programs. Consequently, we have a single measure for
BDNF from each cocaine user, variable periods of abstinence and uncontrolled environmental
factors (inherent in outpatient treatments) that may be interfering with the present data.
IGF-1 and IGFBP-3 in abstinent cocaine users
Numerous studies in mammals have reported that IGF-1 concentrations decline with advanc-
ing age, showing the association of IGF-1 with longevity and age-related diseases (e.g., cancer,
cardiovascular disease, diabetes, osteoporosis, and neurodegenerative diseases) [39,40,41]. We
observed that IGF-1 concentrations correlated significantly with the age of the participants. Ac-
cording to the present results, the history of a pathological use of cocaine did not influence the
association of IGF-1 concentrations and aging because the significant and negative correlation
between both variables was identical to the control group. However, we did not evaluated the
cognitive impairment in the sample [42].
Focusing on cocaine addiction, we observed no changes in the plasma concentrations of
IGF-1 and IGFBP-3 of abstinent users and concentrations did not correlated with addiction-re-
lated variables such as severity cocaine symptom, abstinence or duration of cocaine use. We
did not find literature about an association between IGF-1 and cocaine but other drugs of
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abuse have been investigated. Studies in rodents suggest that IGF-1 is altered in cerebral areas
related to the development of addiction after chronic exposure to morphine [43,44]. In hu-
mans, a recent study in patients with opiate use dependence has demonstrated that serum IGF-
1 is elevated [5]. In addition to opiates, various studies evaluating IGF-1 have been conducted
in alcohol dependent subjects but the authors did not observe any interaction between alcohol
addiction and this peptide in blood or brain [25,45]. However, a recent study in alcohol depen-
dent patients has found that IGF-1 might play a role in the cognitive function in these subjects
[46].
Lack of association with biomarkers of cocaine addiction
Overall, the lack of influence of cocaine addiction on plasma concentrations of BDNF and
IGF-1 was confirmed through multiple analyses of correlation coefficients of these factors with
other circulating molecules sensitive to cocaine addiction and/or psychiatric comorbidity in co-
caine abstinent subjects from similar observational studies [12,13]. Chemokines and pro-in-
flammatory mediators are affected by the cocaine symptom severity, while anti-inflammatory
fatty acid derivatives such as endocannabinoids and their congeners are affected by the history
of pathological use of cocaine and the presence of comorbid disorders. Thus, the significant
correlations between these cocaine-sensitive molecules and BDNF and IGF-1 (and IGFBP-3)
in controls vanished in the cocaine group. However, we observed only one significant correla-
tion after multiple comparisons in the cocaine group, in particular IGFBP-3 and SEA concen-
trations, but the SEA concentrations is not affected by cocaine use unlike other N-acyl-
ethanolamines [13].
Because IGF-1 forms a ternary complex with IGFBP-3 [47], we also studied the association
between both peptides. We detected a positive correlation between plasma concentrations of
IGF-1 and IGFBP-3 in the control participants, but such association was weakly affected by the
lifetime pathological use of cocaine.
BDNF and IGF-1 in abstinent cocaine users with psychiatric comorbidity
Similar to these previous cross-sectional studies in abstinent cocaine users recruited from out-
patient programs, we have detected a high prevalence of comorbid psychiatric disorders, ap-
proximately 60% [12,13]. Although these plasma peptide concentrations were unaltered in
cocaine users, we examined these concentrations according to the diagnosis of primary and co-
caine-induced disorders. Substantial evidence indicates neurotrophic/growth factors such as
BDNF and IGF-1 are involved in the pathogenesis of common psychiatric disorders. We have
indeed observed in this study changes in circulating concentrations of these neurotrophic fac-
tors in mood and anxiety disorders, especially in BDNF.
BDNF in psychiatric comorbidity
Current literature on BDNF and mental disorders is particularly focused on depressive and bi-
polar disorders. Thus, circulating concentrations of BDNF are decreased in depressed patients
compared to controls and that they increase significantly with antidepressant treatment
[48,49,50]. The reduction of plasma BDNF concentration has also been related to suicidal be-
havior in major depression [51] whereas other studies in bipolar patients have found a signifi-
cant association with the severity of depression [52,53], suggesting that plasma BDNF
concentrations may be a marker of depression and/or bipolar disorder. Our findings are con-
sistent with the literature because BDNF concentrations in cocaine users diagnosed with mood
disorders, both primary and cocaine-induced, were found to be decreased. However, only five
cocaine users were identified with this complicated diagnosis and, therefore, the statistical
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significance of this reduction may be called into question. We observed no differences in the
BDNF concentrations of those abstinent subjects displaying primary mood disorders or co-
caine-induced mood disorders separately.
BDNF has also emerged as a potential biomarker for anxiety from preclinical studies in ro-
dents [54]. Translational studies have reported that early stress correlates negatively with pe-
ripheral BDNF concentrations later in life [55]. A recent review of clinical studies showed that
BDNF concentrations were lower in individuals with any anxiety disorder compared to those
without anxiety but this is not consistent across the literature [56]. In support of this, abstinent
cocaine users diagnosed with both primary and cocaine-induced anxiety disorders exhibited a
significant decrease in plasma BDNF, as seen previously with mood disorders. Again, the main
limitation of this observation is related to the reduced number of individuals with this dual
(primary and cocaine-induced anxiety) comorbid diagnosis.
IGF-1 in psychiatric comorbidity
Several studies in old and young populations have shown the association between IGF-1 con-
centrations and depressive symptoms [23,24]. It has been reported that plasma IGF-1 concen-
trations are increased in acute depressed patients [57] and similarly, another study
demonstrated that patients with bipolar disorder have elevated IGF-1 concentrations [58]. Al-
though our data are consistent with these observations and cocaine users with primary mood
disorders displayed an increase in plasma IGF-1 and IGFBP-3 concentrations, these increases
did not reach statistical significance relative to the control group and abstinent users without
mood disorders.
We need to perform additional studies to establish the mechanisms of action of these tro-
phic factors (especially BDNF) and the selectivity in the influence of each factor by a specific
comorbid disorder in cocaine addiction.
Limitations and future perspectives
Although our findings support the importance of monitoring BDNF and IGF-1 in the context
of cocaine addiction with psychiatric comorbidity, we are aware of the limitations of the pres-
ent exploratory study. Firstly, the number of cases reported in our study with comorbid disor-
ders is small and the replication is necessary. We cannot conclude whether these changes in
BDNF and IGF-1 concentrations are exclusive to cocaine addiction or not because new studies
in psychiatric patients with no history of drug use will be necessary to elucidate their role in
mental disorders. Additional studies to determine plasma BDNF and IGF-1 in active cocaine
users are necessary to confirm the lack of effects produced by the presence of cocaine on circu-
lating concentrations of these factors. Further, longitudinal studies during cocaine abstinence
could indicate whether these concentrations are unaltered or time-dependent.
The present study was conducted on outpatient subjects and, therefore we tried to show a
realistic example of individuals seeking treatment in public centers for addiction but without
being isolated from their social and familiar context. Nevertheless, from our results, we believe
that monitoring neurotrophic factors such as BDNF and IGF-1 in cocaine users seeking treat-
ment remains to be investigated to further improve the stratification of these patients taking
into consideration the psychiatric comorbidities.
Supporting Information
S1 Fig. Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3
and variables related to addiction: length of abstinence and amount of cocaine use in absti-
nent cocaine users. A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Black
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dots are individual values. (r) Pearson´s correlation coefficient; (rho) Spearman´s correlation
coefficient; (p) p-value for statistical significance.
(TIF)
S2 Fig. Correlation analyses between plasma concentrations of BDNF, IGF-1 and IGFBP-3
and total number of DSM-IV-TR criteria for cocaine abuse and dependence in abstinent
cocaine users. A) BDNF (pg/mL); B) IGF-1 (ng/mL); and C) IGFBP-3 (μg/mL). Black dots are
individual values. (rho) Spearman´s correlation coefficient; (p) p-value for
statistical significance.
(TIF)
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